Bajaj Healthcare Limited (BAJAJHCARE)

Loading page…

Bajaj Healthcare Limited (BAJAJHCARE) · mywealthgrid

About

Bajaj Healthcare Limited operates in the Indian pharmaceutical sector with a market cap of ₹1,109.57 Cr. Recent quarterly revenues reached ₹165.63 Cr (Jun 2026), positioning it as a mid-scale player. A -25.94% ROE and 27% stock decline over 1 year reflect profitability volatility, though Jun 2026 recovery from Mar's loss signals operational resilience.

Face value: ₹5

Market cap

₹1,088 Cr

P/E

—

P/B

2.2×

Dividend yield

0.8%

ROE

-25.9%

ROCE

3.1%

Debt / equity

0.48

OPM

6.8%

EPS (TTM)

₹-26.5

Book value

₹147.6

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Earnings volatility: Net loss of ₹22.85 Cr in Mar 2026 (-7.16 EPS) rebounded to ₹13.7 Cr in Jun 2026 (+4.07 EPS); verify if loss was one-time or indicates operational fragility
Operating margin collapse: Margins fell from 19.02% (Dec 2025) to 6.75% blended, despite revenue growth; verify drivers and if company can sustain higher levels
Shareholder value destruction: ROE of -25.94% indicates ongoing negative returns; verify if operational improvements or capital allocation changes can reverse this
Generic competition and pricing pressure; verify if products face patent expiry, competitive pricing, or government price caps in India or export markets

Generated analysis · source review pending

Growth drivers

Revenue increased from ₹122.79 Cr (Sep 2024) to ₹165.63 Cr (Jun 2026); verify if driven by volume growth, pricing power, or market share gains in specific segments
Operating margins reached 19.02% (Dec 2025); verify if company can sustain 15–17% levels, which would significantly improve net profit from today's -25.94% ROE
Jun 2026 profit recovery of ₹13.7 Cr from Mar 2026 loss demonstrates resilience; verify if loss was one-time and if underlying operations are improving

Generated analysis · source review pending

1,235 historical price candles were omitted because the exchange source has not been verified.

₹323.0-3.6%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -7.1% (3-yr avg)
−Thin operating margin of 6.8%
−Weak interest coverage of 0.4×

Research score

Structured signal from quality, growth, valuation and momentum.

30/100

Business quality: 16
Valuation: 45

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024
	646	473
Operating expenses	—	—
Operating profit (EBITDA)	111	32
OPM %	17.2%	6.8%
Depreciation	17	28
Interest	18	30
	2	9
Profit before tax	78	-17
Tax	—	—
	43	-84
PAT margin %	6.7%	-17.7%
EPS (₹)	—	—
EPS adjusted (₹)	15.6	-30.4
Annual report	Annual report for Mar 2023	Annual report for Mar 2024

₹ Cr	Mar 2023	Mar 2024	Mar 2025
Equity capital	14	14	16
Reserves	354	265	450
	414	332	223
	116	155	144
Total equity & liabilities	898	765	833
	366	253	222
CWIP	—	—	3
Investments	—	—	0
	—	—	608
Total assets	898	765	833

₹ Cr	Mar 2023	Mar 2024
Cash from operations	-22	92
Cash from investing	-93	-11
Cash from financing	131	-97
Net cash flow	16	-16
Free cash flow	—	—
CFO / Operating profit %	-19.9%	289%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: -27%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: -30%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2023	Mar 2024
Margins
Gross margin %	—	—
EBITDA margin %	17.2%	6.8%
EBIT margin %	14.6%	0.9%
PAT margin %	6.7%	-17.7%
Working capital
Receivable days	—	—
Inventory days	—	—
Payable days	—	—
NWC days	—	—
Leverage
Current ratio	1.15	1.01
Debt to EBITDA	3.72	10.4
Debt to equity	1.13	1.19
Interest coverage	5.5	0.4
Asset turnover	0.72	0.62
Return ratios
Return on assets %	4.8%	-11%
Return on capital employed %	20.6%	3.1%
Return on equity %	11.7%	-30.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	67.69%	67.73%	67.73%	67.73%	59.19%	59.19%	59.19%	59.19%	59.19%	59.19%	58.29%	58.59%
	0.66%	0.74%	0.53%	0.01%	2.46%	1.01%	1.05%	1.09%	1.12%	1.18%	1.98%	2.19%
	0.44%	0.48%	0.44%	0%	1.97%	2.36%	2.52%	3.16%	3%	2.96%	2.91%	1.92%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	31.21%	31.05%	31.3%	32.26%	36.38%	37.44%	37.24%	36.56%	36.69%	36.67%	36.82%	37.3%
No. of shareholders	—	—	—	—	—	—	—	—	38,576	37,953	38,158	41,310

Promoter holding down 9.1 percentage points since Sep 2023.

112 deals · 17 Nov 2022 – 22 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
22 Jul 2026	WESTSTONE MANAGEMENT CONSULTANCY PRIVATE LIMITED	Bulk	NSE	Sell	2,00,000	₹332.91	₹6.66 Cr
29 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	7,23,881	₹347.17	₹25.13 Cr
29 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	7,23,881	₹346.96	₹25.12 Cr
29 Jun 2026	QE SECURITIES LLP	Bulk	NSE	Buy	5,27,910	₹347.89	₹18.37 Cr
29 Jun 2026	QE SECURITIES LLP	Bulk	NSE	Sell	5,27,379	₹345.48	₹18.22 Cr
29 Jun 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	4,80,860	₹347.67	₹16.72 Cr
29 Jun 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	4,76,567	₹347.91	₹16.58 Cr
29 Jun 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	4,53,096	₹347.59	₹15.75 Cr
29 Jun 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	4,53,096	₹347.27	₹15.73 Cr
29 Jun 2026	BLITZQUANT RESEARCH LLP	Bulk	NSE	Buy	2,98,201	₹346.86	₹10.34 Cr

1–10 of 112

1 / 12

Mr. SAJANKUMAR RAMESHWARLAL BAJAJExecutive Director-Chairperson-MD
Mr. ANIL CHAMPALAL JAINExecutive Director-MD
Ms. NAMRATA BAJAJExecutive Director
Mr. PAKSHAL ANIL JAINExecutive Director
Ms. KEJAL NIKEN SHAHNon-Executive - Independent Director
Mr. GOPALAKRISHNAN KNon-Executive - Independent Director
Mr. PARSOTAMBHAI DEVSIBHAI VAGHELANon-Executive - Independent Director
Mrs. PURNIMA DHANRAJ AMINNon-Executive - Independent Director
Mr. UMESH LAXMIDAS BHAVSARNon-Executive - Independent Director
Mr. SHAH SANDEEP RAVINDRANon-Executive - Non Independent Director
Mr. Rohan ParekhChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

1.69%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	329	0.01	0.02%	0.001%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Jul 2026Transcript AI SummaryPPTREC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

24 announcementsExport CSV

22 Sept 2026, 5:18 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

21 Sept 2026, 5:33 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

3 Sept 2026, 11:36 amCorp. Action

Corporate Action-Record Date For Payment Of Final Dividend

Record Date PDF

30 Aug 2026, 2:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

29 Aug 2026, 4:26 pmAGM/EGM

Shareholders Meeting- Dispatch Of Inland Letters To Shareholders

AGM PDF

29 Aug 2026, 4:05 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

29 Aug 2026, 3:54 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

29 Aug 2026, 3:33 pmAGM/EGM

Intimation Of 33Rd Annual General Meeting

AGM PDF

Date	Category	Subject	Filing
22 Sept 2026, 5:18 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
21 Sept 2026, 5:33 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2023	Mar 2024
Margins
Gross margin %	—	—
EBITDA margin %	17.2%	6.8%
EBIT margin %	14.6%	0.9%
PAT margin %	6.7%	-17.7%
Working capital
Receivable days	—	—
Inventory days	—	—
Payable days	—	—
NWC days	—	—
Leverage
Current ratio	1.15	1.01
Debt to EBITDA	3.72	10.4
Debt to equity	1.13	1.19
Interest coverage	5.5	0.4
Asset turnover	0.72	0.62
Return ratios
Return on assets %	4.8%	-11%
Return on capital employed %	20.6%	3.1%
Return on equity %	11.7%	-30.1%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Bajaj Healthcare Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

Ratio timeline

Dividends10

Board meetings1

Stock splits1

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

10

1

1